File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Elevated circulating adipocyte‐fatty acid binding protein levels predict incident cardiovascular events in a community‐based cohort: a 12‐year prospective study

TitleElevated circulating adipocyte‐fatty acid binding protein levels predict incident cardiovascular events in a community‐based cohort: a 12‐year prospective study
Authors
Issue Date2013
Citation
Journal of the American Heart Association, 2013, v. 2 n. 1, no. e004176 How to Cite?
AbstractBACKGROUND: Obesity is closely associated with various cardiovascular diseases (CVDs). Adipose tissue inflammation and perturbation of adipokine secretion may contribute to the pathogenesis of CVD. This study aimed to evaluate whether the 2 most abundant adipokines, adipocyte-fatty acid binding protein (A-FABP) and adiponectin, are independent risk factors predisposing to CVD. METHOD AND RESULTS: We investigated prospectively the 12-year development of CVD in relation to the baseline levels of A-FABP and adiponectin in a population-based community cohort comprising 1847 Chinese subjects recruited from the Hong Kong Cardiovascular Risk Factors Prevalence Study 2 (CRISPS 2) cohort without previous CVD. Baseline serum levels of A-FABP, adiponectin, and C-reactive protein (CRP), an established biomarker predictive of CVD, were measured. In all, 182 (9.9%) of the 1847 Chinese subjects developed CVD during a median follow-up of 9.4 years. The CVD group had more traditional risk factors, higher baseline levels of A-FABP and CRP (both P<0.001), but similar adiponectin levels (P=0.881) compared with the non-CVD group. In Cox regression analysis including both biomarkers, the adjusted HR for A-FABP and CRP for subjects above the optimal cutoff values were 1.57 (95% CI, 1.14 to 2.16; P=0.006) and 1.60 (95% CI, 1.12 to 2.27; P=0.01), respectively, after adjustment for traditional risk factors. The category-free net reclassification index, but not the c-statistic, showed improvement in predictive performance by the addition of A-FABP to the traditional risk factor model (P=0.017). CONCLUSIONS: Circulating A-FABP level predicts the development of CVD after adjustment for traditional risk factors in a community-based cohort. Its clinical use for CVD prediction warrants further validation.
DescriptionOpen Access Journal
Persistent Identifierhttp://hdl.handle.net/10722/182159
ISSN
2023 Impact Factor: 5.0
2023 SCImago Journal Rankings: 2.126
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChow, WSen_US
dc.contributor.authorTso, AWKen_US
dc.contributor.authorXu, Aen_US
dc.contributor.authorYuen, MMAen_US
dc.contributor.authorFong, HYen_US
dc.contributor.authorLam, THen_US
dc.contributor.authorLo, SVen_US
dc.contributor.authorTse, HFen_US
dc.contributor.authorWoo, YCen_US
dc.contributor.authorYeung, CYen_US
dc.contributor.authorCheung, BMYen_US
dc.contributor.authorLam, KSLen_US
dc.date.accessioned2013-04-17T07:27:38Z-
dc.date.available2013-04-17T07:27:38Z-
dc.date.issued2013en_US
dc.identifier.citationJournal of the American Heart Association, 2013, v. 2 n. 1, no. e004176en_US
dc.identifier.issn2047-9980-
dc.identifier.urihttp://hdl.handle.net/10722/182159-
dc.descriptionOpen Access Journal-
dc.description.abstractBACKGROUND: Obesity is closely associated with various cardiovascular diseases (CVDs). Adipose tissue inflammation and perturbation of adipokine secretion may contribute to the pathogenesis of CVD. This study aimed to evaluate whether the 2 most abundant adipokines, adipocyte-fatty acid binding protein (A-FABP) and adiponectin, are independent risk factors predisposing to CVD. METHOD AND RESULTS: We investigated prospectively the 12-year development of CVD in relation to the baseline levels of A-FABP and adiponectin in a population-based community cohort comprising 1847 Chinese subjects recruited from the Hong Kong Cardiovascular Risk Factors Prevalence Study 2 (CRISPS 2) cohort without previous CVD. Baseline serum levels of A-FABP, adiponectin, and C-reactive protein (CRP), an established biomarker predictive of CVD, were measured. In all, 182 (9.9%) of the 1847 Chinese subjects developed CVD during a median follow-up of 9.4 years. The CVD group had more traditional risk factors, higher baseline levels of A-FABP and CRP (both P<0.001), but similar adiponectin levels (P=0.881) compared with the non-CVD group. In Cox regression analysis including both biomarkers, the adjusted HR for A-FABP and CRP for subjects above the optimal cutoff values were 1.57 (95% CI, 1.14 to 2.16; P=0.006) and 1.60 (95% CI, 1.12 to 2.27; P=0.01), respectively, after adjustment for traditional risk factors. The category-free net reclassification index, but not the c-statistic, showed improvement in predictive performance by the addition of A-FABP to the traditional risk factor model (P=0.017). CONCLUSIONS: Circulating A-FABP level predicts the development of CVD after adjustment for traditional risk factors in a community-based cohort. Its clinical use for CVD prediction warrants further validation.-
dc.languageengen_US
dc.relation.ispartofJournal of the American Heart Associationen_US
dc.titleElevated circulating adipocyte‐fatty acid binding protein levels predict incident cardiovascular events in a community‐based cohort: a 12‐year prospective studyen_US
dc.typeArticleen_US
dc.identifier.emailChow, WS: chowws01@hkucc.hku.hken_US
dc.identifier.emailTso, AWK: awktso@hku.hken_US
dc.identifier.emailXu, A: amxu@hkucc.hku.hken_US
dc.identifier.emailFong, HY: kalofong@hku.hken_US
dc.identifier.emailLam, TH: hrmrlth@hkucc.hku.hken_US
dc.identifier.emailTse, HF: hftse@hkucc.hku.hken_US
dc.identifier.emailWoo, YC: wooyucho@hku.hken_US
dc.identifier.emailYeung, CY: ycy167@hku.hken_US
dc.identifier.emailCheung, BMY: mycheung@hku.hken_US
dc.identifier.emailLam, KSL: ksllam@hku.hken_US
dc.identifier.authorityTso, AWK=rp00535en_US
dc.identifier.authorityXu, A=rp00485en_US
dc.identifier.authorityLam, TH=rp00326en_US
dc.identifier.authorityTse, HF=rp00428en_US
dc.identifier.authorityCheung, BMY=rp01321en_US
dc.identifier.authorityLam, KSL=rp00343en_US
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1161/JAHA.112.004176-
dc.identifier.pmid23525430-
dc.identifier.pmcidPMC3603238-
dc.identifier.scopuseid_2-s2.0-84884200484-
dc.identifier.hkuros214026en_US
dc.identifier.hkuros214899-
dc.identifier.volume2en_US
dc.identifier.issue1en_US
dc.identifier.isiWOS:000326336800008-
dc.customcontrol.immutablesml 161108-
dc.identifier.issnl2047-9980-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats